Further Analyses To Delay Ipsen’s Palovarotene Progress In Ultra-Rare Disease
Withdraws US Marketing Submission
Ipsen has withdrawn the US NDA for palovarotene in an ultra-rare bone condition in order to conduct additional data analyses, but intends to resubmit once they are complete.
